Literature DB >> 9884280

Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta.

W C Lee1, C Zhong, S Qian, Y Wan, J Gauldie, Z Mi, P D Robbins, A W Thomson, L Lu.   

Abstract

BACKGROUND: Administration of donor bone marrow (BM)-derived dendritic cell (DC) progenitors (DCp) that are major histocompatibility complex (MHC) class II+ but costimulatory molecule (CD40, CD80, CD86)-deficient can prolong mouse heart allograft survival This is associated with microchimerism and inhibition of antidonor cytotoxic T lymphocyte (CTL) activity. Genetic modification of these donor antigen-presenting cells to express an immunosuppressive molecule(s) may enhance their in vivo survival and potential tolerogenicity.
METHODS: The surface phenotype of B10(H-2b) DCp before and after gene transfer using replication-deficient adenoviral (Ad) vectors was determined by monoclonal antibody (mAb) staining and flow cytometry. Transforming growth factor-beta (TGF-beta) production was quantitated by enzyme-linked immunosorbent assay. Allostimulatory activity of the gene-transduced DCp was ascertained by mixed leukocyte reaction (MLR) and CTL induction. To assess their in vivo migratory activity and survival, the transduced cells were injected subcutaneously into one hind footpad of C3H (H-2k) mice. Tissues (draining popliteal lymph nodes [LN], spleens, and thymi) were removed 1, 2, 7, and 14 days later and stained for donor MHC class II using anti-LA(b) mAb in an immunohistochemical procedure. The mean number of IAb+ cells per unit area was determined.
RESULTS: Transduction with a control Ad vector (Ad-LacZ) at 50 multiplicity of infection slightly increased CD40 and CD86 expression and up-regulated the poor allostimulatory activity of the DCp assessed by MLR and CTL responses. These effects on function were negated in Ad-TGF-beta1-transduced cells. After their injection into mouse footpads, the gene-transduced IAb+ cells were observed in maximal numbers in the popliteal LN at day 1 and in marginal zones and T-dependent areas of spleens (peak at day 7) but were rare in thymi. Transduction with Ad-LacZ reduced the numbers of IAb+ cells identified in both LN and spleens at all time points postinjection, suggesting that the vector alone affected DC life span in allogeneic recipients. TGF-beta1 transgene expression not only fully prevented the reduction in DC induced by Ad transduction alone, but also increased numbers and prolonged the survival of donor cells in the spleen, as shown by a two-to fivefold increase in IAb+ cells at days 2-14 compared with control (Ad-LacZ-transduced) DC.
CONCLUSION: BM-derived DCp can be transduced efficiently to express TGF-beta1 using an Ad vector. They exhibit very poor allostimulatory activity and similar migration characteristics in vivo to unmodified DCp. Survival of TGF-beta gene-transduced DC, however, is enhanced significantly compared with unmodified and (especially) control Ad-LacZ gene-transduced DC. Genetic engineering of donor DC to express the immunosuppressive molecule TGF-beta promotes their survival in allogeneic hosts and may potentiate their previously reported tolerogenicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884280     DOI: 10.1097/00007890-199812270-00040

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  22 in total

1.  Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.

Authors:  Y Morita; J Yang; R Gupta; K Shimizu; E A Shelden; J Endres; J J Mulé; K T McDonagh; D A Fox
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

Review 2.  Dendritic cells and immune regulation in the liver.

Authors:  A H Lau; A W Thomson
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 3.  Alternatives to immunosuppressive drugs in human islet transplantation.

Authors:  Alison Anne Cotterell; Norma Sue Kenyon
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

4.  Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity.

Authors:  Mao-Meng Tiao; Lina Lu; Ran Tao; Lianfu Wang; John J Fung; Shiguang Qian
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

Review 5.  Immunoregulation of dendritic cells.

Authors:  Mark A Wallet; Pradip Sen; Roland Tisch
Journal:  Clin Med Res       Date:  2005-08

Review 6.  Converting nonhuman primate dendritic cells into potent antigen-specific cellular immunosuppressants by genetic modification.

Authors:  Asiedu Clement; Alexander Pereboev; David T Curiel; Sai Sai Dong; Anne Hutchings; Judith M Thomas
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-beta1 for islet transplantation.

Authors:  K L Pothoven; T Kheradmand; Q Yang; J L Houlihan; H Zhang; M Degutes; S D Miller; X Luo
Journal:  Am J Transplant       Date:  2010-07-12       Impact factor: 8.086

8.  Functional study of immature dendritic cells co-transfected with IL-10 and TGF-beta 1 genes in vitro.

Authors:  Lihong Chen; Minglian Qiu; Wubing He; Aimin Huang; Jingfeng Liu
Journal:  Mol Biol Rep       Date:  2012-06       Impact factor: 2.316

9.  Ovine dendritic cells transduced with an adenoviral CTLA4eEGFP fusion protein construct induce hyporesponsiveness to allostimulation.

Authors:  Ashley Newland; Svjetlana Kireta; Graeme Russ; Ravi Krishnan
Journal:  Immunology       Date:  2004-11       Impact factor: 7.397

10.  Prolongation of liver allograft survival by dendritic cells modified with NF-kappaB decoy oligodeoxynucleotides.

Authors:  Ming-Qing Xu; Yu-Ping Suo; Jian-Ping Gong; Ming-Man Zhang; Lu-Nan Yan
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.